CLINICAL TRIAL OF TRIMETHOPRIM-SULFAMETHOXAZOLE IN THE TREATMENT OF VIVAX, OVALE AND FALCIPARUM MALARIA

Abstract

A compound of trimethoprim (TMP) and sulfamethoxazole (SMZ) was effective in the treatment of vivax, ovale and falciparum malaria. Two patients with vivax malaria received 16 mg TMP /80 mg SMZ /kg body weight in 3 divided doses daily for 3 days. A patient with ovale malaria received 10 mg TMP /50 mg SMZ /kg body weight in 4 divided doses daily for 4 days. These doses were followed by 15 mg primaquine daily for 2 weeks. A patient with falciparum malaria received 16 mg TMP /80 mg SMZ /kg body weight in 3 divided doses daily for 3 days. In all patients, radical cures were achieved; neither relapse nor recrudescence has occurred. Trimethoprim-sulfamethoxazole succeeded in causing rapid clearance of asexualparasites from peripheral blood of the patients and producing rapid defervescence. No symptomatic adverse reactions to TMP-SMZ were experienced.